Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The colonic epithelial barrier and mucus layer represent a specialized physiological interface essential for maintaining intestinal homeostasis by segregating the host's systemic environment from the dense microbial population and dietary antigens in the lumen (Johansson et al., 2011, PNAS). This multi-layered system consists of a biochemical barrier (antimicrobial peptides and immunoglobulins), a physical mucus layer (primarily MUC2 mucin), and a cellular barrier composed of epithelial cells linked by tight junctions (Buckley & Turner, 2018, Annu Rev Physiol). The mucus layer is organized into a dense, sterile inner layer and a loose outer layer that houses commensal bacteria. Tight junction proteins, such as claudins and occludin, regulate paracellular permeability, ensuring selective transport while preventing pathogen translocation. Impairment of this barrier, often referred to as "leaky gut," is a central feature in the pathogenesis of inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, where increased permeability leads to chronic immune activation (Odenwald & Turner, 2017, Nat Rev Gastroenterol Hepatol). Therapeutic interventions targeting this barrier include 5-aminosalicylates (e.g., Mesalamine) and novel tight junction regulators like Larazotide acetate, which aim to restore structural integrity and mucosal healing (Lopetuso et al., 2015, Therap Adv Gastroenterol). Additionally, probiotics and certain mucosal protectants are used to reinforce the mucus layer and support the epithelial surface. Maintaining the integrity of this barrier is crucial for preventing systemic inflammation and metabolic dysfunction.
Drugs targeting this system work by enhancing the expression of tight junction proteins (e.g., claudins, occludin), stimulating the production and secretion of MUC2 by goblet cells, and inhibiting pro-inflammatory cytokines like TNF-alpha that increase paracellular permeability (Lopetuso et al., 2015, Therap Adv Gastroenterol).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Colonic epithelial barrier and mucus layer (IEB) (IEB).